SurgoCap Partners LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001960830
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2025 · 12 positions · Total reported value $2.40B · Top-10 concentration 93.5% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 56.2% · 3 new · 1 cut · 5 exited
Active Share (vs S&P 500): 92.4% · vs QQQ: 91.3% — share of the book that differs from index weights (higher = more active) · ranking
In its Q2 2025 13F filing, SurgoCap Partners LP disclosed 12 equity positions with a combined reported value of $2.40B. The filing implies a focused portfolio: its ten largest positions account for 93.5% of reported value. HoldingsHub classifies the profile as Mid / Focused / High Turnover.
The largest disclosed positions as of Q2 2025 were LPLA ($330.50M), BSX ($292.69M), BX ($259.27M). By sector, the heaviest allocations are Financials 31.5%, Technology 21.7%. Versus the prior quarter, allocation shifted toward Technology (+6.3pp), Financials (+4.6pp) and away from Consumer Discretionary (-2.2pp), Health Care (-9.7pp).
Versus the prior quarter, SurgoCap Partners LP opened 3 new positions, trimmed 1 and fully exited 5, a turnover rate of 56.2% of positions. The portfolio's overlap with the prior quarter was 71% of names.
The largest new positions opened in Q2 2025 were INTU ($210.92M), JCI ($115.33M).
Of the 5 positions fully exited versus the prior quarter, the largest were UNH ($142.32M), NOW ($64.44M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2025)
- INTU INTUIT · $210.92M
- JCI JOHNSON CONTROLS INTERNATION · $115.33M
Insider Transactions (Form 4)
Latest SurgoCap Partners LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
SurgoCap Partners LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 13 positions worth $3.09B in total. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-126914 (status: Approved), registered 2022-12-07
- Regulatory AUM (Form ADV): $7.35B as of 2026-06-26
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 1 hedge funds
- Website: surgocap.com
Portfolio Structure
- 13 positions · $3.09B reported value (Q2 2026)
- Top 10 holdings = 92.2% of reported value
- Largest position: TSM (TAIWAN SEMICONDUCTOR MANUFAC) at 14.0%
- Average position size: $237.96M
Sector Tilt
- Information Technology 33.4%
- Health Care 22.1%
- Industrials 20.3%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q2 2026: 3 new, 4 added, 6 reduced, 4 exited
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
881.40K | $330.50M | 13.75% | Reduce | |
| 2 |
|
2.72M | $292.69M | 12.17% | Add | |
| 3 |
|
1.73M | $259.27M | 10.78% | Add | |
| 4 |
|
926.00K | $255.93M | 10.64% | Reduce | |
| 5 |
|
167.84K | $224.75M | 9.35% | Reduce | |
| 6 |
|
267.79K | $210.92M | 8.77% | New | |
| 7 |
|
268.15K | $196.50M | 8.17% | Reduce | |
| 8 |
|
12.22M | $167.60M | 6.97% | Add | |
| 9 |
|
703.53K | $165.65M | 6.89% | Add | |
| 10 |
|
196.78K | $145.24M | 6.04% | Reduce | |
| 11 |
|
1.09M | $115.33M | 4.80% | New | |
| 12 |
|
150.00K | $39.95M | 1.66% | Reduce | |
FAQ
What did SurgoCap Partners LP buy in 2025-Q2?
In its 2025-Q2 13F filing, SurgoCap Partners LP reported 12 equity positions worth $2.40B in aggregate; its largest disclosed positions were LPLA ($330.50M), BSX ($292.69M), BX ($259.27M).
How large is SurgoCap Partners LP's portfolio?
SurgoCap Partners LP reported $2.40B of long equity holdings across 12 positions as of 2025-Q2. Top-10 holdings account for 93.5% of reported value.
What is SurgoCap Partners LP's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.